Royal DSM, a global science-based company active in health, nutrition and materials, today announces a change in the leadership of its DSM Biomedical unit. Christophe Dardel, President DSM Biomedical, will pursue his career outside DSM.
To ensure the continuing progress in Biomedical, Mr. Gerard de Reuver will assume responsibility for DSM Biomedical with immediate effect until a long-term successor is appointed.
Gerard, a Dutch national, joined DSM in 2002 after obtaining a University degree in Pharmacy & Biology and gaining senior leadership experience at amongst others Pfizer, Unilever, Perstorp, Gemini and Perkin Elmer. He held positions as President DSM Anti-Infectives and Vice President Crisis & Change. From April 2010 until August 2015, he held the position of President DSM Dyneema and played a key role in developing and strengthening the DSM Dyneema organization.
Source: DSM
The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.
The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.
“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.
